Ana Cecilia Bardossy

Ana Cecilia Bardossy

Auto-generated profile, based on publicly available information

Ana Cecilia Bardossy

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
VCVeronica P. Costantini
Veronica P. Costantini
KNKenny Nguyen
Kenny Nguyen
ZLZoe Lyski
Zoe Lyski
SNShannon Novosad
Shannon Novosad
ABAna C. Bardossy
Ana C. Bardossy
JVJan Vinjé
Jan Vinjé
Oral fluids offer a noninvasive sampling method for the detection of Abs. Quantification of IgA and IgG Abs in saliva allows studies of the mucosal and systemic immune response after natural infection or vaccination. We developed and validated an enzyme immunoassay (EIA) to detect and quantify salivary IgA and IgG Abs against the prefusion-stabilized form of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein expressed in suspension-adapted HEK-293 cells. Normalization against total Ab isotype was performed to account for specimen differences, such as collection time and sample volume. Saliva samples collected from 187 SARS-CoV-2 confirmed cases enrolled in 2 cohorts and 373 prepandemic saliva samples were tested. The sensitivity of both EIAs was high (IgA, 95.5%; IgG, 89.7%) without compromising specificity (IgA, 99%; IgG, 97%). No cross-reactivity with endemic coronaviruses was observed. The limit of detection for SARS-CoV-2 salivary IgA and IgG assays were 1.98 ng/ml and 0.30 ng/ml, respectively. Salivary IgA and IgG Abs were detected earlier in patients with mild COVID-19 symptoms than in severe cases. However, severe cases showed higher salivary Ab titers than those with a mild infection. Salivary IgA titers quickly decreased after 6 wk in mild cases but remained detectable until at least week 10 in severe cases. Salivary IgG titers remained high for all patients, regardless of disease severity. In conclusion, EIAs for both IgA and IgG had high specificity and sensitivity for the confirmation of current or recent SARS-CoV-2 infections and evaluation of the IgA and IgG immune response.

1 March 2021 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
FTFarrell A. Tobolowsky
Farrell A. Tobolowsky
ABAna C. Bardossy
Ana C. Bardossy
DCDustin W. Currie
Dustin W. Currie
NSNoah G. Schwartz
Noah G. Schwartz
RZRachael L.T. Zacks
Rachael L.T. Zacks
ARAgam K. Rao
Agam K. Rao

16 September 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
ABAna Cecilia Bardossy
Ana Cecilia Bardossy
JAJesenia Angeles
Jesenia Angeles
SBStephanie Booth
Stephanie Booth
LFLucy Fike
Lucy Fike
AWAshley Wadley
Ashley Wadley
SNShannon A. Novosad
Shannon A. Novosad
Key Points: Dialysis facilities voluntarily reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in vaccinated dialysis patients detected between January 1, 2021, and August 31, 2021, to the Centers for Disease Control and Prevention. Among 4087 patients reported, most were symptomatic, a third required hospitalization, and 9% died within 30 days of diagnosis. Monitoring SARS-CoV-2 infections and outcomes among vaccinated people on dialysis provides valuable insight into this population.

8 February 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
ABAna C. Bardossy
Ana C. Bardossy
ESEmily A. Snavely
Emily A. Snavely
ENElizabeth Nazarian
Elizabeth Nazarian
PAPallavi Annambhotla
Pallavi Annambhotla
SBSridhar V. Basavaraju
Sridhar V. Basavaraju
LELauren Epstein
Lauren Epstein

30 December 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
ABAna Cecilia Bardossy
Ana Cecilia Bardossy
LKLauren Korhonen
Lauren Korhonen
SSSabrina Schatzman
Sabrina Schatzman
PGPaige Gable
Paige Gable
CHCarolyn Herzig
Carolyn Herzig
SNShannon Novosad
Shannon Novosad
Key Points: Patients with ESKD on dialysis had persistent and intermittently positive RT-PCR tests for severe acute respiratory syndrome coronavirus 2. Evidence for presence of infectious virus was lacking in most cases. A symptom-based approach, instead of a test-based approach, should be used to decide when to discontinue transmission-based precautions. Background: Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity. Methods: From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens. Results: Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2–specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative. Conclusions: Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2–RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR–positive results in the presence of SARS-CoV-2–specific antibodies, but without replication-competent virus detected.

6 November 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
DSDipesh Solanky
Dipesh Solanky
ABAna Cecilia Bardossy
Ana Cecilia Bardossy
SNShannon Novosad
Shannon Novosad
HMHeather Moulton-Meissner
Heather Moulton-Meissner
MAMatthew Arduino
Matthew Arduino
KPKiran M. Perkins
Kiran M. Perkins
In this summary of US Centers for Disease Control and Prevention (CDC) consultations with state and local health departments concerning their bronchoscope-associated investigations from 2014 through 2022, bronchoscope reprocessing gaps and exposure to nonsterile water sources appeared to be the major routes of transmission of infectious pathogens, which were primarily water-associated bacteria.